Immuron Plans Phase 2 Trial for IMM-529 following FDA review - BioSpace
Immuron completes pre-IND meeting with FDA on IMM-529 for Clostridioides difficile infection (CDI), plans IND application for 1H 2025, and targets prevention, recurrence protection, and treatment of CDI with a 3-target approach.
Reference News
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - BioSpace
Immuron completes pre-IND meeting with FDA on IMM-529 for Clostridioides difficile infection (CDI), plans IND application for 1H 2025, and targets prevention, recurrence protection, and treatment of CDI with a 3-target approach.